Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats

P. Chan, I. M. Liu, T. F. Tzeng, T. L. Yang, Juei Tang Cheng

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Aims: We investigated the mechanism(s) by which valsartan, a selective antagonist of angiotensin subtype 1 (AT1) receptor, decreased plasma glucose in streptozotocin (STZ)-induced diabetic rats. Methods: The plasma glucose concentration was assessed by the glucose oxidase method. The concentration of β-endorphin in plasma or medium incubating adrenal medulla was measured using an enzyme-linked immunosorbent assay. The mRNA levels of the subtype 4 form of glucose transporter (GLUT4) in soleus muscle and phosphoenolpyruvate carboxykinase (PEPCK) in the liver were detected by Northern blotting analysis, while the protein levels of GLUT4 in isolated soleus muscle and hepatic PEPCK were investigated using Western blotting analysis. Results: A single intravenous injection of valsartan dose-dependently increased plasma β-endorphin-like immunoreactivity (BER) in parallel with the lowering of plasma glucose concentration in STZ-induced diabetic rats. Naloxone and naloxonazine inhibited the plasma glucose-lowering action of valsartan at doses sufficient to block opioid μ-receptors. In contrast to its action in wild-type diabetic mice, valsartan failed to modify plasma glucose in opioid μ-receptor knockout diabetic mice. Bilateral adrenalectomy in STZ-induced diabetic rats eliminated both the plasma glucose-lowering action and the plasma BER-elevating action of valsartan. In the isolated adrenal medulla of STZ-induced diabetic rats, angiotensin II (Ang II) or valsartan did not affect spontaneous BER secretion. Activation of cholinergic receptors by 1.0 μmol/l acetylcholine (ACh) enhanced BER secretion from the isolated adrenal medulla of STZ-induced diabetic rats, but not in the presence of 1.0 nmol/l Ang II, while valsartan reversed this inhibition by Ang II in a concentration-dependent manner. Treatment of STZ-induced diabetic rats with valsartan (0.2 mg/kg) three times daily for 3 days resulted in an increase in gene expression of GLUT4 in soleus muscle and impeded the reduction of elevated mRNA or protein level of hepatic PEPCK. Both of these effects were blocked by opioid μ-receptor antagonist. Conclusions: The results suggest that blockade of AT1 receptor by valsartan may enhance the adrenal β-endorphin secretion induced by ACh, activating the opioid μ-receptors to increase glucose utilization and/or to decrease hepatic gluconeogenesis, resulting in the reduction of plasma glucose in STZ-induced diabetic rats.

Original languageEnglish
Pages (from-to)39-49
Number of pages11
JournalDiabetes, Obesity and Metabolism
Volume9
Issue number1
DOIs
Publication statusPublished - Jan 2007

Fingerprint

Valsartan
Angiotensins
Streptozocin
Glucose
Endorphins
Phosphoenolpyruvate
Adrenal Medulla
Opioid Receptors
Angiotensin II
Skeletal Muscle
Liver
Acetylcholine
Glucose Transporter Type 4
Glucose Oxidase
Messenger RNA
Gluconeogenesis
Narcotic Antagonists
Facilitative Glucose Transport Proteins
Adrenalectomy
Cholinergic Receptors

Keywords

  • 5β-endorphin
  • Angiotensin
  • Opioid μ-receptors
  • Phosphoenolpyruvate carboxykinase
  • Streptozotocin-induced diabetic rats
  • Subtype 4 form of glucose transporter
  • Valsartan

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats. / Chan, P.; Liu, I. M.; Tzeng, T. F.; Yang, T. L.; Cheng, Juei Tang.

In: Diabetes, Obesity and Metabolism, Vol. 9, No. 1, 01.2007, p. 39-49.

Research output: Contribution to journalArticle

@article{af20c872bebf4f509f60cc26b4d4f780,
title = "Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats",
abstract = "Aims: We investigated the mechanism(s) by which valsartan, a selective antagonist of angiotensin subtype 1 (AT1) receptor, decreased plasma glucose in streptozotocin (STZ)-induced diabetic rats. Methods: The plasma glucose concentration was assessed by the glucose oxidase method. The concentration of β-endorphin in plasma or medium incubating adrenal medulla was measured using an enzyme-linked immunosorbent assay. The mRNA levels of the subtype 4 form of glucose transporter (GLUT4) in soleus muscle and phosphoenolpyruvate carboxykinase (PEPCK) in the liver were detected by Northern blotting analysis, while the protein levels of GLUT4 in isolated soleus muscle and hepatic PEPCK were investigated using Western blotting analysis. Results: A single intravenous injection of valsartan dose-dependently increased plasma β-endorphin-like immunoreactivity (BER) in parallel with the lowering of plasma glucose concentration in STZ-induced diabetic rats. Naloxone and naloxonazine inhibited the plasma glucose-lowering action of valsartan at doses sufficient to block opioid μ-receptors. In contrast to its action in wild-type diabetic mice, valsartan failed to modify plasma glucose in opioid μ-receptor knockout diabetic mice. Bilateral adrenalectomy in STZ-induced diabetic rats eliminated both the plasma glucose-lowering action and the plasma BER-elevating action of valsartan. In the isolated adrenal medulla of STZ-induced diabetic rats, angiotensin II (Ang II) or valsartan did not affect spontaneous BER secretion. Activation of cholinergic receptors by 1.0 μmol/l acetylcholine (ACh) enhanced BER secretion from the isolated adrenal medulla of STZ-induced diabetic rats, but not in the presence of 1.0 nmol/l Ang II, while valsartan reversed this inhibition by Ang II in a concentration-dependent manner. Treatment of STZ-induced diabetic rats with valsartan (0.2 mg/kg) three times daily for 3 days resulted in an increase in gene expression of GLUT4 in soleus muscle and impeded the reduction of elevated mRNA or protein level of hepatic PEPCK. Both of these effects were blocked by opioid μ-receptor antagonist. Conclusions: The results suggest that blockade of AT1 receptor by valsartan may enhance the adrenal β-endorphin secretion induced by ACh, activating the opioid μ-receptors to increase glucose utilization and/or to decrease hepatic gluconeogenesis, resulting in the reduction of plasma glucose in STZ-induced diabetic rats.",
keywords = "5β-endorphin, Angiotensin, Opioid μ-receptors, Phosphoenolpyruvate carboxykinase, Streptozotocin-induced diabetic rats, Subtype 4 form of glucose transporter, Valsartan",
author = "P. Chan and Liu, {I. M.} and Tzeng, {T. F.} and Yang, {T. L.} and Cheng, {Juei Tang}",
year = "2007",
month = "1",
doi = "10.1111/j.1463-1326.2005.00566.x",
language = "English",
volume = "9",
pages = "39--49",
journal = "Diabetes, Obesity and Metabolism",
issn = "1462-8902",
publisher = "Wiley-Blackwell",
number = "1",

}

TY - JOUR

T1 - Mechanism for blockade of angiotensin subtype 1 receptors to lower plasma glucose in streptozotocin-induced diabetic rats

AU - Chan, P.

AU - Liu, I. M.

AU - Tzeng, T. F.

AU - Yang, T. L.

AU - Cheng, Juei Tang

PY - 2007/1

Y1 - 2007/1

N2 - Aims: We investigated the mechanism(s) by which valsartan, a selective antagonist of angiotensin subtype 1 (AT1) receptor, decreased plasma glucose in streptozotocin (STZ)-induced diabetic rats. Methods: The plasma glucose concentration was assessed by the glucose oxidase method. The concentration of β-endorphin in plasma or medium incubating adrenal medulla was measured using an enzyme-linked immunosorbent assay. The mRNA levels of the subtype 4 form of glucose transporter (GLUT4) in soleus muscle and phosphoenolpyruvate carboxykinase (PEPCK) in the liver were detected by Northern blotting analysis, while the protein levels of GLUT4 in isolated soleus muscle and hepatic PEPCK were investigated using Western blotting analysis. Results: A single intravenous injection of valsartan dose-dependently increased plasma β-endorphin-like immunoreactivity (BER) in parallel with the lowering of plasma glucose concentration in STZ-induced diabetic rats. Naloxone and naloxonazine inhibited the plasma glucose-lowering action of valsartan at doses sufficient to block opioid μ-receptors. In contrast to its action in wild-type diabetic mice, valsartan failed to modify plasma glucose in opioid μ-receptor knockout diabetic mice. Bilateral adrenalectomy in STZ-induced diabetic rats eliminated both the plasma glucose-lowering action and the plasma BER-elevating action of valsartan. In the isolated adrenal medulla of STZ-induced diabetic rats, angiotensin II (Ang II) or valsartan did not affect spontaneous BER secretion. Activation of cholinergic receptors by 1.0 μmol/l acetylcholine (ACh) enhanced BER secretion from the isolated adrenal medulla of STZ-induced diabetic rats, but not in the presence of 1.0 nmol/l Ang II, while valsartan reversed this inhibition by Ang II in a concentration-dependent manner. Treatment of STZ-induced diabetic rats with valsartan (0.2 mg/kg) three times daily for 3 days resulted in an increase in gene expression of GLUT4 in soleus muscle and impeded the reduction of elevated mRNA or protein level of hepatic PEPCK. Both of these effects were blocked by opioid μ-receptor antagonist. Conclusions: The results suggest that blockade of AT1 receptor by valsartan may enhance the adrenal β-endorphin secretion induced by ACh, activating the opioid μ-receptors to increase glucose utilization and/or to decrease hepatic gluconeogenesis, resulting in the reduction of plasma glucose in STZ-induced diabetic rats.

AB - Aims: We investigated the mechanism(s) by which valsartan, a selective antagonist of angiotensin subtype 1 (AT1) receptor, decreased plasma glucose in streptozotocin (STZ)-induced diabetic rats. Methods: The plasma glucose concentration was assessed by the glucose oxidase method. The concentration of β-endorphin in plasma or medium incubating adrenal medulla was measured using an enzyme-linked immunosorbent assay. The mRNA levels of the subtype 4 form of glucose transporter (GLUT4) in soleus muscle and phosphoenolpyruvate carboxykinase (PEPCK) in the liver were detected by Northern blotting analysis, while the protein levels of GLUT4 in isolated soleus muscle and hepatic PEPCK were investigated using Western blotting analysis. Results: A single intravenous injection of valsartan dose-dependently increased plasma β-endorphin-like immunoreactivity (BER) in parallel with the lowering of plasma glucose concentration in STZ-induced diabetic rats. Naloxone and naloxonazine inhibited the plasma glucose-lowering action of valsartan at doses sufficient to block opioid μ-receptors. In contrast to its action in wild-type diabetic mice, valsartan failed to modify plasma glucose in opioid μ-receptor knockout diabetic mice. Bilateral adrenalectomy in STZ-induced diabetic rats eliminated both the plasma glucose-lowering action and the plasma BER-elevating action of valsartan. In the isolated adrenal medulla of STZ-induced diabetic rats, angiotensin II (Ang II) or valsartan did not affect spontaneous BER secretion. Activation of cholinergic receptors by 1.0 μmol/l acetylcholine (ACh) enhanced BER secretion from the isolated adrenal medulla of STZ-induced diabetic rats, but not in the presence of 1.0 nmol/l Ang II, while valsartan reversed this inhibition by Ang II in a concentration-dependent manner. Treatment of STZ-induced diabetic rats with valsartan (0.2 mg/kg) three times daily for 3 days resulted in an increase in gene expression of GLUT4 in soleus muscle and impeded the reduction of elevated mRNA or protein level of hepatic PEPCK. Both of these effects were blocked by opioid μ-receptor antagonist. Conclusions: The results suggest that blockade of AT1 receptor by valsartan may enhance the adrenal β-endorphin secretion induced by ACh, activating the opioid μ-receptors to increase glucose utilization and/or to decrease hepatic gluconeogenesis, resulting in the reduction of plasma glucose in STZ-induced diabetic rats.

KW - 5β-endorphin

KW - Angiotensin

KW - Opioid μ-receptors

KW - Phosphoenolpyruvate carboxykinase

KW - Streptozotocin-induced diabetic rats

KW - Subtype 4 form of glucose transporter

KW - Valsartan

UR - http://www.scopus.com/inward/record.url?scp=33845543316&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33845543316&partnerID=8YFLogxK

U2 - 10.1111/j.1463-1326.2005.00566.x

DO - 10.1111/j.1463-1326.2005.00566.x

M3 - Article

VL - 9

SP - 39

EP - 49

JO - Diabetes, Obesity and Metabolism

JF - Diabetes, Obesity and Metabolism

SN - 1462-8902

IS - 1

ER -